Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Brain Cancer
New GLIADEL Wafer data presented at SNO meeting
December 28th, 2004
Guilford Pharmaceuticals, Inc., (GLFD) announced that new data for GLIADEL Wafer (polifeprosan 20 with carmustine implant) were presented at the Society for Neuro-Oncology (SNO) annual meeting in Toronto, Ontario, Canada. The Society for Neuro-Oncology is regarded as the pre-eminent scientific society for clinical research on brain cancer. The data, which are part of a 3-year, prospective patient registry called PROLONG (Prospective Look at Outcomes Nationally with GLIADEL Wafer), suggest that GLIADEL may be useful in controlling local disease progression in patients with metastatic brain cancer. The frequency of metastatic brain cancer has increased in recent years and...
Source: Cancer Weekly (2004-12-28)
|
